Seres Therapeutics swings to Q3 net loss of $16.29 million

Bitget2026/11/04 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Seres Therapeutics swung to a third-quarter 2026 net loss of $16.29 million from a year-earlier profit of $8.2 million.
Revenue rose 69% year over year to $593,000.
Research and development expenses fell 56% year over year to $5.59 million, reflecting lower costs and reduced activities.
Cash totaled $17.5 million at September 30; operations are funded through first-quarter 2027, including October’s $12.5 million Nestlé payment.
Plans call for submitting a SER-155 study design for preventing immune checkpoint inhibitor-related enterocolitis to the FDA in first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869900) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Seres Therapeutics swings to Q3 net loss of $16.29 million

You may also like

Crypto prices